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HEPARIN-BINDING IGF-1 PROVIDES SUSTAINED DELIVERY
OF IGF-1 TO CARTILAGE IN VIVO
R. Miller1, A. Grodzinsky1, K. Cummings2, R.T. Lee2, P. Patwari2
1MIT, Cambridge, MA; 2Brigham and Women’s Hosp., Cambridge,
MA
Purpose: IGF-1 stimulates cartilage growth and repair but is not a
practical therapy due to its short half-life in vivo. We modiﬁed IGF-1
by adding a heparin-binding domain, creating HB-IGF-1. HB-IGF-
1 is retained in bovine cartilage tissue and promotes sustained
proteoglycan synthesis compared to IGF-1.
In the present study, we examined the mechanism of HB-IGF-1
retention in cartilage and tested whether HB-IGF-1 could provide
sustained in vivo delivery of IGF-1 to rat cartilage after intra-
articular injection.
Methods: Protein Production: Both HB-IGF-1 and control IGF-1
were expressed with Xpress and 6x-His tags in E. coli and puriﬁed
by Ni-NTA afﬁnity and reverse-phase chromatography.
Bovine Cartilage with Enzyme Treatment: Cartilage disks (3 mm
diam, 0.5 mm thick) from calf femoropatellar grooves were cultured
in serum-free medium with 500nM HB-IGF-1 or IGF-1 for 2 days.
At Day 2, disks were washed and treated with either no enzyme,
chondroitinase ABC (0.4U/mL), or heparitinase (0.036U/mL). At
Day 4, half of the chondroitinase-treated disks were treated
with heparitinase; all other disks were incubated in enzyme-free
medium. On Day 6, IGF remaining in the tissue was detected by
Western analysis.
CHO cell binding: Mutant CHO cells lacking heparan sulfate (strain
pgsD-677) and wildtype CHO (K1) cells were incubated in serum-
free medium with 100nM HB-IGF-1 or IGF-1 for 3 h, washed, and
analyzed by Western.
Biacore: Chondroitin sulfate (CS) and heparan sulfate (HS) were
biotinylated and bound to a streptavidin-coated Biacore chip. HB-
IGF-1 or IGF-1 was ﬂowed across the chip to determine the
maximum amount of IGF-1 bound (RUmax).
Intra-articular injection in rat: 10ug HB-IGF-1, 10ug IGF-1, or saline
alone was injected into the knee joints of 2-month-old male
Sprague-Dawley rats. After one day, joint tissues were harvested
and extracted. Portions of extracts with equal total protein were
analyzed by Western.
Results: HB-IGF-1 but not IGF-1 remained bound to bovine
cartilage explants after 6 days (Fig. 1, No Enzyme). Treatment with
chondroitinase ABC greatly decreased binding, while heparitinase
had no effect (Fig. 1, C’ase and H’ase). In addition, HB-IGF-
1 bound CHO cells lacking HS equally well as wild-type cells,
indicating that HS is not required for binding. Biacore analysis
showed that HB-IGF-1 bound to both HS and CS at 250-500nM,
although HS binding was stronger than CS binding (Fig. 2). Control
IGF-1 did not bind any of the GAGs at concentrations up to 1 uM.
One day after intra-articular injection, HB-IGF-1 was retained in
rat knee articular cartilage, whereas IGF-1 was undetectable (Fig.
3, Articular Cartilage). HB-IGF-1 was detectable despite stronger
immunoreactivity of IGF-1 (Fig. 3, Protein Standards). Neither
IGF-1 was detected in patellar tendon extracts (Fig. 3, Tendon),
consistent with better delivery to the CS-rich cartilage.
Figure 1
Figure 2
Figure 3
Conclusions: HB-IGF-1 is retained in rat knee cartilage longer
than IGF-1 after intra-articular injection. Surprisingly, although
HB-IGF-1 binds most strongly to heparan sulfate, the enhanced
retention of HB-IGF-1 in cells and cartilage appears primarily due
to binding of chondroitin sulfate, which is much more abundant
in cartilage than HS. HB-IGF-1 may be a new therapeutic for
sustained and relatively speciﬁc delivery of IGF-1 to cartilage.
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A SINGLE INTRA-ARTICULAR INJECTION OF INTERLEUKIN
1 RECEPTOR ANTAGONIST IS INSUFFICIENT TO RESTORE
GAIT DEFICIENCY RESULTING FROM INTERLEUKIN-1
MEDIATED CARTILAGE DESTRUCTION IN A RODENT
MODEL
K.D. Allen, S.B. Adams Jr., D. Latt, D.L. Nettles, L.A. Setton
Duke Univ., Durham, NC
Purpose: Interleukin-1 (IL1) plays a pivotal role in osteoarthritis
(OA), regulating inﬂammatory and catabolic processes. IL1 re-
ceptor antagonist (IL1Ra) can block IL1-induced inﬂammation in
rheumatoid arthritis, and intra-articular injection of IL1Ra has been
evaluated as an OA treatment. IL1-mediated joint inﬂammation and
destruction has been modeled in the rat through intra-articular in-
jection of rat dermal ﬁbroblasts modiﬁed to over-express human
IL1β. Here, we examine the efﬁcacy of a single intra-articular
IL1Ra injection in reversing pain and functional loss in this model.
Methods: Pre-treatment measures of mechanical sensitivity and
gait were determined for male Wistar rats (n=14, day=-2). Right
knee joints then received a 30 μL injection containing 12,500
rat dermal ﬁbroblasts modiﬁed to overexpress human IL1β (day=-
1). The following day, rats received either a 30 μL intra-articular
injection of IL1Ra (0.65 mg/mL) or saline (n=7, day=0). Gait was
quantiﬁed on post-treatment day 2 and 6 using high-speed video,
and mechanical withdrawal thresholds were measured on post-
treatment day 1, 3, and 5.
Results: Following injection of IL1β overexpressing cells, rats
locomoted with faster velocities and longer stride lengths on post-
treatment day 2 and 6 relative to pre-treatment data (p<0.001);
however, rats treated with IL1Ra selected slower velocities than
rats receiving saline (p=0.056). Rats receiving saline demonstrated
asymmetric gait on post-treatment day 2 and 6 with a delayed time
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to right foot strike. This may indicate a hesitancy to shift weight
from the contralateral limb (left) to the injected limb (right). Asym-
metries were also observed in rats treated with IL1Ra; however,
asymmetry shifts occurred in both directions (Fig. 1). Both groups
demonstrated a strong preference for the contralateral limb on
post-treatment day 2 and 6, spending approximately 10% more
time on the contralateral limb relative to the injected limb. Fur-
thermore, rats treated with IL1Ra exhibited aerial phases where
neither hind limb was in ground contact (Fig. 2). Sensitivity in the
injected limb, detected as lower mechanical withdrawal thresholds,
increased in both groups with no differences between the groups
(Fig. 3).
Conclusions: Rats receiving a unilateral knee injection of hIL1β
overexpressing cells locomoted at higher velocities, used asym-
metric gait with a preference for the uninjected limb, and exhibited
increased mechanical sensitivity. A single treatment with IL1Ra
was associated with more symmetric gaits; however, treatment
with IL1Ra showed little tendency to modify any other measure at
up to 6 days post-treatment. While intra-articular injection of IL1Ra
has therapeutic potential for reversing the effects of IL1-mediated
Figure 3
inﬂammation, these data indicate that a single injection is not
sufﬁcient to restore joint function or reduce heightened sensitivity
associated with IL1β overexpression. This is likely driven by rapid
and efﬁcient IL1Ra clearance from the joint space and motivates
studies of sustained intra-articular delivery of IL1Ra.
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ANALGESIC EFFECTS OF INTRA-ARTICULAR BOTULINUM
TOXIN TYPE B IN A MURINE MODEL OF CHRONIC
DEGENERATIVE ARTHRITIS
S. Anderson, P. McGarraugh, S. Frizelle, M. Mahowald, H. Krug
VA Med. Ctr., Mpls, MN
Purpose: New therapies for refractory arthritis pain are needed.
Studies have shown that inﬂammation within joints may cause
peripheral and central sensitization of neurons leading to spon-
taneous joint pain at rest and hyperalgesia with stimulation. In-
ﬂammatory mediators induced by neuropeptide release activate
peripheral nerve receptors. Given this peripheral sensitization we
hypothesize arthritis pain may be treated by intra-articular (IA)
neurotoxins. Efﬁcacy of IA botulinum toxin (BoNT) Type A for re-
fractory arthritis pain, and in murine models has recently been
reported, prompting interest in screening other botulinum toxins
that may prove more effective for arthritis pain. Currently BoNT
A and BoNT Type B are the best characterized and most used
clinically. BoNT B may produce greater pain relief and may be
effective in different types of pain than BoNT A. We hypothesized
that BoNT B would reduce chronic arthritic knee pain, testing this
in a murine model of chronic degenerative arthritis
Methods: Chronic arthritis was produced in C57Bl6 mice by IA
injection of 10 IU Collagenase in 10 μl NS in the left knee peaking
at 4 weeks. BoNT B (MYOBLOC) 0.02 IU in 5 μl of NS was given
IA in the left knee 3 days before testing. Normal right knee served
as internal control. Mice were studied before, after induction of
arthritis and after IA BoNT B. Video gait analysis performed using
Treadscan™ video gait analysis system hardware and software.
In this system lameness was quantiﬁed as the standard deviation
of stance to stride ratio (STA/STR). Knees were examined for
bony swelling indicative of arthritis. Evoked pain behavior was
measured by tallying ﬁghts + vocalizations/1 min in response to
repeated ﬁrm palpation of the knee by a single examiner trained
for consistency and precision. Gait and strength were observed
visually and graded semi-quantitatively as a consensus score
among 3 examiners. Strength was measured as ability to grasp
and cling. Student’s t-test used for statistical comparisons.
Results: Swelling, visual and video gait analysis revealed signif-
icant alterations following IA collagenase, indicating induction of
arthritis (swelling P= 0.0016, gait P= 0.0081, variability of STA/STR
P=0.0128). Evoked pain behaviors increased with arthritis, but
were not statistically signiﬁcant (p=0.3274). Signiﬁcant improve-
ment in visual gait scores (p=0.0045) and video gait analysis
STA/STR variability (p < 0.0001) were noted following IA BoNT
